People Not Receiving Antiretroviral and Treatment U=U and Services in One Year through Bilateral FY 2013 Sequestration

This graphic from AVAC Report 2012 illustrates the potential effects of US federal budget sequestration on HIV prevention and Treatment U=U implementation in 2013.

Follow-on trials based on RV144: Strategy includes development and research tracks

This graphic from AVAC Report 2012 shows several planned vaccine trials building on the results of the RV144 AIDS vaccine trial.

AVAC Playbook 2012-2013: Progress toward global goals

AVAC first published its Playbook of global goals for ending AIDS in late 2011. This infographic from the AVAC Report 2012 builds on the objectives from 2011 and identifies five priorities for action in 2013.

Defining Combination Prevention: Ongoing trials in sub-Saharan Africa

Stepping Up the Pace: VMMC accelerates in priority countries

As this graphic from AVAC Report 2012 illustrates, the pace of implementation of VMMC for HIV prevention has increased dramatically since 2010 in priority countries.

HIV Prevention Research: Defining moments since 2010

Published in AVAC Report 2011, this timeline shows the HIV prevention scientific breakthroughs from July 2010 to Nov 2011, including the CAPRISA 004, iPrEx and Partners PrEP trials.

Many Opportunities for HIV Prevention

To end AIDS, we need HIV prevention options that are highly effective before, during and after exposure or infection. This graphic from AVAC Report 2011 lists some of these tools.

AVAC Playbook 2012

AVAC Playbook 2012 includes AVAC’s analysis of what the top strategic goals should be on a global level, and particularly in hard-hit countries, over the year 2012. It also includes AVAC’s organizational priorities for contributing to these goals.

Invest Now to Save Lives and Funds

Published in AVAC Report 2011, this graphic was adapted from the paper authored by UNAIDS and others that advocated for a new “investment framework” for the AIDS response. It models changes in incidence and mortality if the world increases its investment in evidence-based AIDS programs–and what will happen if it doesn’t.

PxWire January-March 2011, Vol. 4, No. 1

PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of PxWire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis.